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Short Communication:
The Veterans Aging Cohort Study Index Is an Effective
Tool to Assess Baseline Frailty Status
in a Contemporary Cohort of HIV-Infected Persons
Gerome V. Escota,1 Pragna Patel,2 John T. Brooks,2 Tim Bush,2 Lois Conley,2 Jason Baker,3
Erna Milunka Kojic,4 John Hammer,5 and Nur F. O¨nen,1 for the SUN Study Investigators
Abstract
The Veterans Aging Cohort Study (VACS) Index has previously been used to identify frail HIV-infected
persons. However, data demonstrating the independent association between the VACS Index and baseline
frailty status is lacking. Furthermore, the ability of the VACS Index to also reflect transitions in frailty status
over time is unknown. We used data from the Study to Understand the Natural History of HIV and AIDS in the
Era of Effective Therapy (SUN Study) to determine independent association of baseline frailty status with the
VACS Index. We also evaluated VACS Index changes with frailty status transitions over time. We included 303
participants (median age 48 years, 76% men, 57% non-Hispanic white, 91% with plasma HIV RNA < 400
copies/ml, and median CD4+ cell count 595 cells/ml) with baseline and follow-up frailty assessments and used the
Fried’s criteria to define frailty status. There were 184 (61%) nonfrail, 112 (37%) prefrail, and seven (2%) frail
participants at baseline. Prefrail/frail participants had significantly higher median VACS Index scores compared
with nonfrail participants (18 versus 10, p< 0.001). In multivariable analysis, prefrailty/frailty was independently
associated with a higher VACS Index score (odds ratio 1.025, p= 0.019). After a median follow-up of 12 months,
participants who remained prefrail/frail compared to those who remained nonfrail continued to have higher median
VACS Index scores. The VACS Index score did not significantly change with transitions in frailty status over time.
Our study highlights the potential utility of the VACS Index in frailty assessment within the clinical setting.
Frailty is a clinical syndrome resulting from dysre-gulation of multiple physiologic systems that leads to low
endurance, poor strength, low physical activity, increased
hospitalization, and mortality.1 Studies derived from the
Multicenter AIDS Cohort Study (MACS) have shown that
frailty occurs at a much younger age among HIV-infected
persons compared with demographically matched HIV-
uninfected individuals.2,3 Among the aging HIV-infected
population, in whom frailty prevalence has been estimated to
range from 2% to 20%4 the role of chronic inflammation in the
multifactorial pathogenesis of this syndrome is increasingly
recognized.4 Frailty has previously been shown to be inde-
pendently associated with lowCD4+ cell count, higher plasma
HIV RNA, longer duration of HIV infection, previous history
of opportunistic infections, and depression.2,4
The Veterans Aging Cohort Study (VACS) Index is a
multivariable risk assessment tool that has been shown to
accurately predict 5-year all-cause mortality risk among
HIV-infected persons.5 It has also been shown to predict
morbidity, including hospitalizations and medical intensive
care unit admissions,6 and correlate with HIV-related chronic
inflammation.7 Because frailty and the VACS Index predict
the same outcomes, the VACS Index has been used in two
recent studies as a surrogate marker to identify frail HIV-
infected persons.8,9 Another study has also shown that the
median VACS Index scores of frail HIV-infected persons
were significantly higher compared to nonfrail individuals.10
Despite these data, the association of the VACS Index with
frailty independent of other frailty predictors has not yet
been demonstrated. Furthermore, it is unknown whether
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transitions in frailty status over time could also be reflected
by changes in the VACS Index.
In this study, we determined the independent association of
the VACS Index score with frailty as defined by the Fried’s
criteria, the most widely accepted definition of frailty.1 Fur-
thermore, we evaluated the dynamics of the VACS Index
with changes in frailty status over time.
We used data from the Study to Understand the Natural
History of HIV and AIDS in the Era of Effective Therapy
(SUN Study), an observational cohort funded by the Centers
for Disease Control and Prevention (CDC). The SUN Study
design has been previously reported.11 Briefly, 700 partici-
pants from seven HIV clinics in four cities in the United
States (Saint Louis, Denver, Minneapolis, and Providence)
were enrolled from March 2004 to June 2006 and followed
until June 2012. Participants were recruited if they were naive
to, or had previously received combination antiretroviral
therapy (cART). Frailty assessments were performed from
June 2010 to May 2012. Participants with initial and follow-
up frailty assessments were included. Participants with
missing frailty assessments and incomplete VACS Index
information were excluded.
Nonfrail, prefrail, and frail states were defined by the pres-
enceof0, 1–2, and ‡ 3offive established criteria (unintentional
weight loss, physical inactivity, exhaustion,weakgrip strength,
and slow walking time), respectively1 (Table 1). All study
coordinators were trained to conduct the frailty assessment
uniformly. The VACS Index, which utilizes HIV-related and
unrelated variables (Table 2),was calculated for all participants
during the initial and follow-up frailty assessments.
Previous frailty studies have shown that prefrailty is an
intermediary in the spectrum of nonfrailty through frailty and
the majority of persons pass through this stage before tran-
sitioning to a frail or nonfrail state both in the HIV-infected4
and HIV-uninfected population.12 Because of the low prev-
alence of frailty in our cohort, we combined prefrail and frail
states to increase statistical power. Association of the VACS
Index and its components with prefrail/frail status at baseline
and at follow-up assessments was determined using the v2
test for categorical variables and the Student’s t-test or the
Wilcoxon rank-sum test for continuous variables depending
on whether variables were normally distributed or not. To
address multiple comparisons, we used the Bonferroni method
and determined that comparisons with p values< 0.006 were
statistically significant.
We then assessed byunivariate andmultivariable analysis the
association of the VACS Index and several HIV-related and
unrelated variables with prefrail/frail status. Associations in
univariate analysis with p< 0.10 were then modeled using
stepwise logistic regression for the outcomeof prefrailty/frailty;
for this analysis, p values< 0.05 were considered statistically
significant.All analyseswere conducted using SPSSversion 22.
Evaluations of 303 participants were available for analysis.
The median age was 48 years [interquartile range (IQR) 42–
54 years], 76% were men, 57% were non-Hispanic white,
93% were prescribed cART, 91% had a plasma HIV RNA
< 400 copies/ml, and the median baseline CD4 + cell count
was 595 cells/ml (IQR 441–782 cells/ml). Since frailty as-
sessments were conducted only from 2010 to 2012, the ma-
jority of the participants excluded from this analysis had
Table 1. Fried’s Criteria with Modification of Assessment of Physical Activity
Criteria Definition
Unintentional weight lossa > 10 pound weight loss documented in the last year or ‡ 5% of the previous body weight
Physical inactivity Subjects answering 3 when asked whether their health limits vigorous activities such
as running, lifting heavy objects, participating in strenuous sports:
1= not at all, 2 = yes, limited a little, or 3 = yes, limited a lot
Exhaustion Subjects answering 2 or 3 to either one of two statements:
How often have you felt that:
(a) everything you did was an effort or
(b) I could not ‘‘get going’’
0 = rarely ( <1 day), 1 = some of the time (1–2 days), 2 = occasionally (3–4 days),
or 3 =most of the time (5–7 days)
Weak grip strength Male Female
BMI kg/m2 kg BMI kg/m2 kg
£ 24 £ 29 £ 23 £ 17
24.1–26.0 £ 30 23.1–26.0 £ 17.3
26.1–28.0 £ 30 26.1–29.0 £ 18
> 28 £ 32 > 29 £ 21
Slow walking time Male Female
Height (cm) Secondsb Height (cm) Seconds
£ 173 ‡ 7 £ 159 ‡ 7
> 173 ‡ 6 > 159 ‡ 6
aFor patients who had attended clinic for < 12 months, unintentional weight loss was defined as > 5 pounds in the last 6 months or ‡ 2.5%
of the previous year’s body weight.
bWalking time was determined by asking participants to walk 15 feet at their usual pace.
BMI, body mass index. Nonfrail, prefrail, and frail states were defined by the presence of 0, 1–2, and ‡ 3 of five established criteria.
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either a missing baseline or follow-up frailty assessment.
Prior to the start of frailty assessments, 27 participants were
deceased, 51 were lost to follow-up, 64 moved to another
center, and 105 withdrew from the study. Compared with
participants excluded from this analysis, the analysis cohort
was slightly older by 1.6 years ( p = 0.02). Otherwise, the
analysis cohort and the excluded participants had similar
baseline characteristics.
There were 184 (61%) nonfrail, 112 (37%) prefrail, and
only seven (2%) frail participants (Table 3). Prefrail/frail
participants had significantly higher median VACS Index
scores compared with nonfrail participants. They also had
higher hepatitis C infection and lower median hemoglobin. In
multivariable analysis, a higher VACS Index score was sig-
nificantly associated with prefrail/frail status independent of
nonwhite race, current non-full-employment, and depression
(Table 4). When the components of the VACS Index were
analyzed in this multivariable model, only hepatitis C in-
fection remained associated with prefrail/frail status inde-
pendent of nonwhite race, current non-full-employment, and
depression (Supplementary Table S1; Supplementary Data
are available online at www.liebertpub.com/aid).
Participants had a median follow-up of 12 months (range,
8–16 months). The majority of nonfrail [115 of 184 (63%)]
Table 2. The VACS Index
Variables Value Points
Age (years) < 50 0
50–64 12
‡ 65 27






HIV-1 RNA (copies/ml) < 500 0
500–1 · 105 7
‡ 1· 105 14




FIB-4a < 1.45 0
1.45–3.25 6
> 3.25 25





aFIB 4 is calculated as (years of age ·AST)/(platelet count·
109/liter· square root of ALT).
bEstimated glomerular filtration rate is calculated as 186.3· (serum
creatinine- 1.154)· (age- 0.203)· (0.742 for women)· (1.21 if black).
cHepatitis C virus (HCV) infection is defined as a diagnosis with
a positive antibody test or detectable virus.
VACS, Veterans Aging Cohort Study; RNA, ribonucleic acid;
FIB-4, an index of liver fibrosis; eGFR, estimated glomerular
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and prefrail [77 of 112 (69%)] participants at baseline did not
change frailty status. Conversely, the majority of frail [five of
seven (71%)] participants at baseline transitioned to a prefrail
status. Furthermore, among 184 nonfrail participants at
baseline, 68 (37%) participants transitioned to a prefrail state
compared to only one (0.5%) participant who transitioned
directly to a frail state. Participants who remained prefrail/
frail compared to those who remained nonfrail continued to
have higher median VACS Index scores (18 versus 12,
p < 0.001) and were more likely to have hepatitis C infection
(22% versus 3%, p< 0.001) and a lower median hemoglobin
(13.7 versus 15.3 g/dl, p < 0.001) (statistical comparison not
shown in Table 3). Nonfrail participants who transitioned to
prefrailty/frailty had lower median hemoglobin than those
who remained nonfrail (14.2 versus 15.3 g/dl; p < 0.001).
Thirty-three (28%) prefrail/frail participants transitioned to a
nonfrail state. There were no major differences in the com-
ponents of the VACS Index between participants who
remained prefrail/frail versus those who became nonfrail.
Transitions between nonfrail and prefrail/frail categories
were not associated with significant changes in the VACS
Index score.
Thus, we have demonstrated that HIV-related prefrailty/
frailty, prevalent even among young HIV-infected persons
with well-controlled HIV infection, was independently as-
sociated with a higher VACS Index. Although this associa-
tion is modest, it supports the use of the VACS Index to
identify HIV-infected persons with prefrailty and frailty. The
high prevalence of hepatitis C infection and lower hemo-
globin among prefrail and frail participants largely contrib-
uted to a higher VACS Index score in these groups.
Our findings suggest that low hemoglobin and especially
hepatitis C infection could be important factors in the path-
ogenesis of HIV-related frailty. Both factors are associated
with increased markers of inflammation, which is also char-
acteristic of HIV-related frailty.4 In the general population,
low hemoglobin has also been directly associated with poor
muscle strength and physical performance,13 which are all
part of the Fried’s frailty phenotype. Hepatitis C infection
was also found to independently predict development of
frailty among HIV-infected and HIV-uninfected men in the
recent MACS study.3
Our findings also highlight the contribution of race, de-
pression, and poor social factors in the occurrence of HIV-
related prefrailty/frailty. Unlike poor socioeconomic status,
race has not been consistently shown to be associated with
HIV-associated frailty.14 Several studies among HIV-
infected persons taking cART have shown an independent
association between depression and unemployment.3,15 The
reason behind this link between race, depression, and poor
social factors with HIV-associated frailty is likely multifac-
torial. It mirrors the strong association of low socioeconomic
status with poorer health outcomes and increased all-cause
mortality in the general population.16,17
We have also documented longitudinal changes in frailty
status and correspondingly examined dynamic changes in the
VACS Index. We found that the VACS Index failed to reflect
transitions between nonfrail and prefrail/frail categories over
1 year. This may be because the majority of our participants
had fully suppressed plasma HIV RNA, relatively robust
CD4 cell counts, and little, if any, advanced renal or liver
injury. Thus, using the VACS Index to monitor frailty tran-
sitions in the clinical setting may be limited.
The low sample size and number of frail participants in our
study and the overall low VACS Index scores of our partic-
ipants limited our analysis. Furthermore, the study was lim-
ited by the performance of only two frailty assessments
during a short follow-up observation period (8–16 months).
In the recent MACS study that analyzed participants who
completed at least six frailty assessment visits over 4 years,
Table 4. Baseline Factors Independently Associated with Initial Prefrailty/Frailty
Assessment on Multivariable Analysis, the SUN Study, 2010–2012









VACS Indexa 1.037 1.019–1.055 < 0.001 1.025 1.004–1.046 0.019
Male 0.448 0.262–0.767 0.003
Nonwhite race 2.715 1.688–4.368 < 0.001 2.140 1.217–3.763 0.008
Current not fully employed 5.110 3.010–8.674 < 0.001 2.652 1.461–4.814 0.001
Current tobacco use 1.749 1.091–2.805 0.020
Ever tobacco use 1.709 1.027–2.843 0.039
Alcohol use 0.382 0.235–0.621 < 0.001
Depression 4.749 2.892–7.800 < 0.001 4.230 2.420–7.392 < 0.001
Nadir CD4 + cell countb 0.998 0.997–1.000 0.065
Duration of HIV infectionc 1.060 1.012–1.111 0.015
Current cART use 0.405 0.161–1.023 0.056
Duration of cART use (years)d 1.015 0.945–1.091 0.675
Prior opportunistic infection 1.185 0.702–2.001 0.525
aPer 1 unit increase in VACS Index.
bPer 1 cell/mm3 decrease in CD4 + cell count.
cPer 1 year increase in HIV infection duration.
dPer 1 year increase in duration of cART use.
SUN Study, Study to Understand the Natural History of HIV/AIDS; VACS, Veterans Aging Cohort Study; cART, combination
antiretroviral therapy.
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the expression of the frailty phenotype was found to be
transient with almost half of the participants expressing the
frailty phenotype at only one visit.3 Of note, the Fried’s
frailty criteria have also not been validated among younger
HIV-uninfected individuals and among HIV-infected persons.
In conclusion, we have demonstrated the association of the
VACS Index with baseline prefrailty and frailty among HIV-
infected persons independent of other frailty predictors.
Further studies with a larger sample size, longer follow-up,
and more frequent frailty assessments may be warranted to
determine whether the VACS Index can be used to monitor
transitions in frailty status over time. Our findings highlight
the promising use of the VACS Index in the assessment of
baseline frailty status within the clinical setting, and under-
score its potential utility in the care of our aging HIV-infected
population.
Author Disclosure Statement
No competing financial interests exist.
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